Table 1 Summary of clinical, pathological, and molecular characteristics of the molecular subtypes of DLBCL

T/HRLBCL

CD20, CD45,k (CD79A/B), CD15^—, (CD30^—),

Progenitor cell of germinal center B- cell

Gene expression profiling

Unknown

~1–4 %

Median age: 30–50

Gender dominance: male

Extranodal (vague nodularity is rare)

BOB1, PU.1^+/—, CT2, PAX5, (BCL2), BCL6, IRF4^—

Diffuse pattern with predominance of reactive T cells

Bone marrow involvement: ~ 30 %

Survival ~ 50 % at 5 years

Curable ~ 45 %

GCB-

CD20, CD10, CD22, (CD30), (BCL2), (MYC), BCL6, GCET, HGAL, LMO2, PTEN^+/—, IRF4^—, FOX ^—,

Germinal center B-cell

Gene expression profiling

Unknown

~17 %

Median age 61

DLBCL

Gender dominance: male ≥ female

Nodal and extranodal

Bone marrow involvement: ~ 15 %

Survival ~ 60 % at 5 years

Curable ~ 50 %

ABC-

CD20, CD22, (CD30), (CD79A/B), IRF4, FOXP1, (BCL2), (MYC), BCL6^+/—, GCET^—, LMO2^—,

Post-germinal center B- cell

Gene expression profiling

Unknown

~15 %

Median age: 66

DLBCL

Gender dominance: male ≥ female

Nodal and extranodal

Bone marrow involvement: ~ 15 %

Survival ~ 40 % at 5 years

Curable ~30 %

PMLBCL

CD19, CD20, CD22, CD30, CD45, CD79A, CD3^—, CD10^—, CD21^— BOB1, PU.1, OCT2, PAX5, BCL6, IRF4, c-REL, TRAF1

Post- thymic B- cell

Gene expression profiling

Unknown

~6 %

Median age: 33

Gender dominance: female Mediastinal, thoracic > nodal Bone marrow involvement: rare Survival: > 60 % at 5 years

Curable: > 60 %